Free Trial

Biomerica (BMRA) Stock Price, News & Analysis

+0.02 (+3.28%)
(As of 05/29/2024 ET)
Today's Range
50-Day Range
52-Week Range
38,907 shs
Average Volume
183,413 shs
Market Capitalization
$10.60 million
P/E Ratio
Dividend Yield
Price Target
BMRA stock logo

About Biomerica Stock (NASDAQ:BMRA)

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

BMRA Stock Price History

BMRA Stock News Headlines

Biomerica expands offices, secures new patents
Biomerica provides update on inFoods® IBS expansion
Biomerica Reports Third Quarter 2024 Financial Results
Biomerica Inc BMRA
Biomerica Inc.
BMRA Mar 2024 2.500 call
Biomerica Reports Second Quarter 2024 Financial Results
Nasdaq Gains 100 Points; Biomerica Shares Spike Higher
REPEAT - Biomerica Reports First Quarter 2024 Financial Results
See More Headlines
Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Industry, Sector and Symbol

Diagnostic substances
Current Symbol
Year Founded


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$5.34 million
Book Value
$0.70 per share


Free Float
Market Cap
$10.60 million

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Zackary S. Irani (Age 58)
    CEO & Director
    Comp: $141.25k
  • Mr. Allen C. Barbieri (Age 66)
    Executive Vice-Chairman of the Board & Corporate Secretary
    Comp: $126.25k
  • Mr. Gary Lu CPA (Age 43)
    Principal Accounting Officer & CFO
    Comp: $260k
  • Ms. Lucy Liu Ph.D.
    Director of Manufacturing & Technical Operations
  • Mr. Robert W. Carlson
    Chief Commercial Officer

BMRA Stock Analysis - Frequently Asked Questions

How have BMRA shares performed in 2024?

Biomerica's stock was trading at $1.25 at the beginning of the year. Since then, BMRA shares have decreased by 53.0% and is now trading at $0.5880.
View the best growth stocks for 2024 here

Are investors shorting Biomerica?

Biomerica saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 343,400 shares, an increase of 219.7% from the April 30th total of 107,400 shares. Based on an average trading volume of 227,700 shares, the short-interest ratio is currently 1.5 days.
View Biomerica's Short Interest

When is Biomerica's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 23rd 2024.
View our BMRA earnings forecast

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) released its quarterly earnings data on Friday, April, 12th. The company reported ($0.11) earnings per share for the quarter. The business had revenue of $1.02 million for the quarter. Biomerica had a negative net margin of 117.46% and a negative trailing twelve-month return on equity of 64.00%.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

Who are Biomerica's major shareholders?

Biomerica's stock is owned by many different institutional and retail investors. Top institutional investors include Russell Investments Group Ltd. (1.34%), Fore Capital LLC (0.35%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allen Barbieri, Catherine Coste and Zackary S Irani.
View institutional ownership trends

How do I buy shares of Biomerica?

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BMRA) was last updated on 5/29/2024 by Staff

From Our Partners